相关实验视频

Updated: May 3, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

识别晚年抑郁症的个性化大脑生物标志物的挑战

Kayla Hannon¹, Janine Bijsterbosch¹

¹Department of Radiology, Washington University in St Louis, St Louis MO, 63110, USA.

Advances in geriatric medicine and research

|February 13, 2024

概括

对晚年抑郁症 (LLD) 的神经影像生物标志物显示不一致的结果. 应对构造变性和异质性等挑战是可靠LLD研究的关键.

科学领域:

神经科学是一个神经科学.
精神病学是一个精神病学.
老年学是指老年学的学科.

背景情况:

神经成像研究已经确定了晚年抑郁症 (LLD) 的潜在生物标志物,例如白质强度过高和海马体积减少.
然而,对LLD这些神经成像生物标志物进行研究的研究中发现的结果缺乏一致性和可复制性.

研究的目的:

讨论LLD神经成像生物标志物研究中阻碍可复制性的挑战.
提出提高未来LLD神经成像研究可靠性和有效性的策略.

主要方法:

审查和讨论关于LLD的神经成像生物标志物的现有文献.
确定关键挑战,包括构造变性,病因异质性和实验严谨性.
为未来的研究方向制定建议.

主要成果:

对LLD的神经成像生物标志物研究缺乏趋同是一个重大问题.
挑战源于不一致的定义,LLD的各种原因和不同的研究方法.
拟议的解决方案包括标准化构造,增加样本大小,使用多式联运数据和采用个性化分析.

结论:

结构的标准化,更大的样本大小,多模式数据集成和个性化分析模型对于推动LLD神经成像生物标志物研究至关重要.
解决这些方法挑战将提高神经成像在理解和治疗晚年抑郁症方面的可靠性和临床实用性.

关键词:

生物标志物生物标志物晚年生活中的抑郁症抑郁症神经成像是一种神经成像.个性化精神病学个性化精神病学

更多相关视频

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

相关概念视频

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...